Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Blanca Xicoy, María-José Jiménez, Olga García, Joan Bargay, Violeta Martínez-Robles, Salut Brunet, María-Jesús Arilla, Jaime Pérez de Oteyza, Rafael Andreu, Francisco-Javier Casaño, Carlos-Javier Cervero, Alicia Bailén, María Díez, Bernardo González, Ana-Isabel Vicente, Carme Pedro, Teresa Bernal, Elisa Luño, María-Teresa Cedena, Luis Palomera, Adriana Simiele, José-Manuel Calvo, Víctor Marco, Eduardo Gómez, Marta Gómez, David Gallardo, Juan Muñoz, Raquel de Paz, Javier Grau, Josep-Maria Ribera, Luis-Enrique Benlloch & Guillermo Sanz. (2014) Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leukemia & Lymphoma 55:6, pages 1300-1303.
Read now
Read now
Pasquale Niscola, Massimiliano Palombi, Monika Malgorzata Trawinska, Andrea Tendas, Marco Giovannini, Laura Scaramucci, Alessio Perrotti & Paolo de Fabritiis. (2013) Managing myelodysplastic syndromes in very old patients: a teaching case report. Clinical Interventions in Aging 8, pages 391-394.
Read now
Read now
Articles from other publishers (11)
Sang Eun Yoon, Junhun Cho, Yeon Jeong Kim, Seok Jin Kim & Won Seog Kim. (2022) Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 22:11, pages e972-e980.
Crossref
Crossref
Syed Saqib Ali, Ruchika Raj, Tejinder Kaur, Brenna Weadick, Debasis Nayak, Minnsung No, Jane Protos, Hannah Odom, Kajal Desai, Avinash K. Persaud, Joanne Wang & Rajgopal Govindarajan. (2022) Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective. Cancers 14:13, pages 3113.
Crossref
Crossref
Spyros A. Papiris, Panagiotis Tsirigotis, Caroline Kannengiesser, Lykourgos Kolilekas, Konstantinos Gkirkas, Andriana I. Papaioannou, Patrick Revy, Paschalina Giouleka, Georgia Papadaki, Konstantinos Kagouridis, Vassiliki Pappa, Raphael Borie, Catherine Boileau, Demosthenes Bouros, Bruno Crestani & Effrosyni D. Manali. (2019) Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison. Respiratory Research 20:1.
Crossref
Crossref
Ricard Mesia, Paolo Bossi, Aaron R. Hansen, Ching-Yun Hsieh, Lisa F. Licitra, Eng-Huat Tan, Peng Chen, JulieAnn Miller, Lilian L. Siu & Robert I. Haddad. (2019) Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. European Journal of Cancer 123, pages 138-145.
Crossref
Crossref
Tijs Louwies, Casey O. Ligon, Anthony C. Johnson & Beverley Greenwood‐Van Meerveld. (2018) Targeting epigenetic mechanisms for chronic visceral pain: A valid approach for the development of novel therapeutics. Neurogastroenterology & Motility 31:3, pages e13500.
Crossref
Crossref
Da Jung Kim, Ho Sup Lee, Joon-Ho Moon, Sang Kyun Sohn, Hyeoung Joon Kim, June-Won Cheong, Deog-Yeon Jo, Hawk Kim, Hyewon Lee, Soo-Mee Bang, Won Sik Lee, Yong Park, Mark Hong Lee, Jae Hoon Lee, Sung Hwa Bae & Min Kyoung Kim. (2017) Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. Oncotarget 8:45, pages 79414-79424.
Crossref
Crossref
Ellen Niederberger, Eduard Resch, Michael J. Parnham & Gerd Geisslinger. (2017) Drugging the pain epigenome. Nature Reviews Neurology 13:7, pages 434-447.
Crossref
Crossref
Vasiliki Pappa, Achilles Anagnostopoulos, Eleni Bouronikou, Evangelos Briasoulis, Ioannis Kotsianidis, Maria Pagoni, Panagiotis Zikos, Konstantinos Tsionos, Nora Viniou, John Meletis, Helen Papadaki, Anna Kioumi, Athanasios Galanopoulos, Elisavet-Christine Vervessou, Elias Poulakidas, Panagiotis Karmas, Kiki Karvounis & Argiris Symeonidis. (2016) A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece. International Journal of Hematology 105:2, pages 184-195.
Crossref
Crossref
Hyun Ae Jung, Chi Hoon Maeng, Moonjin Kim, Sungmin Kim, Chul Won Jung & Jun Ho Jang. (2015) Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients. Oncotarget 6:18, pages 16653-16662.
Crossref
Crossref
D Ma, Q Fang, P Wang, R Gao, J Sun, Y Li, X Y Hu & J S Wang. (2015) Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome. Gene Therapy 22:4, pages 287-296.
Crossref
Crossref
Angela Nebbioso, Vincenzo Carafa, Rosaria Benedetti & Lucia Altucci. (2012) Trials with ‘epigenetic’ drugs: An update. Molecular Oncology 6:6, pages 657-682.
Crossref
Crossref